Options for the third and subsequent lines of drug treatment for patients with metastatic colorectal cancer. A review

Authors:

Abstract
Despite advancements in molecular genetic profiling and the development of new antitumor pharmacotherapies, treatment options for individuals with metastatic colorectal cancer remain restricted, with median overall survival (OS) ranging from 16 to 34 months, contingent upon the clinical context. In this patient population, the majority begin first-line therapy; approximately 80% receive second-line treatment; and around 40–60% progress to third-line therapy. The substantial number of patients eligible for further antitumor treatment after two lines underscores the need to examine the selection of third- and subsequent-line therapy. This review consolidates current approaches to selecting third- and subsequent-line treatments for patients with refractory metastatic colorectal cancer, including regorafenib, fruquintinib, and trifluridine/tipiracil in both monotherapy and combination regimens. The narrative review incorporates findings from randomized Phase III trials (CORRECT, CONCUR, FRESCO/FRESCO-2, RECOURSE, SUNLIGHT, TASCO1/6), real-world practice registries (CONSIGN, PRECONNECT), network meta-analyses, and ongoing clinical trials (ClinicalTrials.gov, data current to March 2026). The literature review indicates that regorafenib, fruquintinib, and FTD/TPI demonstrate superior efficacy compared with placebo when combined with best supportive care. Notably, the combination of FTD/TPI with bevacizumab yields the most favorable OS, with a median of 10.8 months and a relative risk of 0.61. Network meta-analyses rank FTD/TPI with bevacizumab as optimal for OS (SUCRA 0.92). However, assessments of individual subgroups suggest that certain drugs may be more advantageous in specific contexts. The selection of third-line therapy requires a personalized approach that considers mutational status, tumor location, prior treatments, and tolerability. The combination of FTD/TPI with bevacizumab appears to be the most promising treatment option; however, direct comparisons with regorafenib and fruquintinib are warranted.

This publication has 64 references indexed in Scilit: